Cell therapy weekly: cord blood for autism and promising gene therapy safety data

This week: first double-blind crossover study of children with autism demonstrates improvement after cord blood treatment and Celgene commences Juno buy-out.

Go to the profile of RegMedNet
Feb 09, 2018
0
1
Upvote 0 Comment

The news highlights:

Autologous cord blood demonstrated to be safe and lead to improvement in children with autism
Celgene commences tender offer for Juno Therapeutics
First-in-man AAV9-based gene therapy found to be well tolerated in patients with Sanfilippo syndrome

Autologous cord blood demonstrated to be safe and lead to improvement in children with autism

In research funded by the Cord Blood Registry and published in Stem Cells Translational Medicine, treatment of autistic children with their own newborn cord blood was found to be safe and led to improvements in test scores for socialization.

"The Vineland Adaptive Behavior Scale for Socialization, one of the tests commonly used to measure real-world functional abilities, showed significant improvement after 12 weeks of cord blood treatment over placebo," explained primary investigator Michael Chez, Sutter Neuroscience Institute (CA, USA). However, when correcting for possible statistical chance when looking at many outcome variables, this observed significance no longer reached significance, particular as the pilot research study only looked at 30 patients.

Read more

Back to top of page

Celgene commences tender offer for Juno Therapeutics

Celgene Corporation (UK) has commenced their tender offer for Juno Therapeutics (WA, USA) at US$87 per share. The acquisition will position Celgene as a leader in cellular immunotherapy and accelerate Juno’s development pipeline.

Speaking in an earlier press release, Mark J. Alles, Celgene's Chief Executive Officer commented: "The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers. Juno's advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene's global leadership in hematology and adds new drivers for growth beyond 2020."

Read more

Back to top of page

First-in-man AAV9-based gene therapy found to be well tolerated in patients with Sanfilippo syndrome

Abeona Therapeutics Inc. (TX, USA) has reported promising preliminary safety and biopotency data for ABO-101, their gene therapy for mucopolysaccharidosis type IIIB (MPS IIB). This genetic disorder leads to neurocognitive decline and loss of speech and mobility. No adverse events were reported after 30 days at an intravenous dose of 2E13vg/kg and ABO-101 has been granted Rare Pediatric Disease Designation by the FDA, and Orphan Product Designation by both the FDA and the EMA.

 “MPS IIIB is a devastating and progressive lysosomal storage disease with no approved treatment options. The first patient treated with ABO-101 has demonstrated that the systemic AAV gene transfer is well-tolerated, and the preliminary evidence of biopotency in the CNS and periphery is very encouraging," stated Kevin M. Flanigan, principal investigator and Director of the Center for Gene Therapy at Nationwide Children's Hospital and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine (both OH, USA).

“We are especially pleased to see reductions in several key biopotency markers, including the reductions in cerebral spinal fluid, urine and plasma heparan sulfate and normalization of plasma NAGLU enzyme activity at days seven, 14 and 30 post-transfer.”

Read more

Back to top of page

For more weekly cell therapy news, read previous editions of the cell therapy weekly.

Go to the profile of RegMedNet

RegMedNet

eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

1 Comments

Go to the profile of James L. Sherley, M.D., Ph.D.

The trial of  Chez et al., reported in SCTM to evaluate possible beneficial effects of UCB on autism spectrum diseases, has two potentially confounding design features.

1) A cross-over design is ill-advised for investigations of stem cell treatments, which if in fact efficacious might have long-lived effects.   Long-lived treatment effects will confound the comparison of treated versus placebo in a cross-over study.

2) DMSO the cryoprotectant for UCB units, is also a potent cell differentiation agent, including differentiation of neuronal cells.   This study did not control for effects of DMSO.   If beneficial effects are present, though not detected with statistical confidence in the reported trial, they might be due to DMSO instead of the cells in the treatment.  Differentiation effects are also long-lived and will be confounded in a cross-over study.

James Sherley

Asymmetrex

Go to the profile of Freya Leask
Freya Leask 5 months ago

Interesting thoughts, James - thanks for sharing!